Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA intercalating anti-tumour agents.

B C Baguley1

  • 1Cancer Research Laboratory, University of Auckland Medical School, New Zealand.

Anti-Cancer Drug Design
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of tumor blood flow.

Methods in molecular medicine·2011
Same author

Analysis of radiation-induced changes to human melanoma cultures using a mathematical model.

Cell proliferation·2010
Same author

Cell cycle times of short-term cultures of brain cancers as predictors of survival.

British journal of cancer·2008
Same author

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.

Cancer chemotherapy and pharmacology·2006
Same author

In vitro modelling of human tumour behaviour in drug discovery programmes.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.

British journal of cancer·2004
Same journal

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·2002
Same journal

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Anti-cancer drug design·2002
Same journal

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Anti-cancer drug design·2002
Same journal

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Anti-cancer drug design·2002
Same journal

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Anti-cancer drug design·2002
Same journal

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

Anti-cancer drug design·2002
See all related articles

Understanding DNA intercalators is key to developing effective anti-cancer drugs. This review explores how these compounds interact with DNA and proteins to achieve anti-tumour activity, guiding future drug design.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Limited clinical utility of known DNA intercalators for anti-cancer effects.
  • Need to identify key properties for effective anti-tumour activity.

Purpose of the Study:

  • Review mechanisms of DNA intercalator-macromolecule interactions.
  • Explore principles of non-covalent drug-DNA binding.
  • Guide design of novel anti-cancer agents.

Main Methods:

  • Literature review of DNA intercalating anti-tumour agents.
  • Analysis of non-covalent drug-DNA interactions.
  • Discussion of ternary complex formation (DNA, drug, protein).

Main Results:

Related Experiment Videos

  • DNA intercalation can lead to anti-tumour activity through complex mechanisms.
  • DNA topoisomerase II is a key target for intercalating drugs.
  • Factors influencing drug transport and resistance are critical.

    • Conclusions:

    • Complex interactions govern DNA intercalator efficacy.
    • Understanding ternary complexes and drug transport is vital.
    • Guiding principles can enhance future anti-cancer drug development.